Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: peter michaelson who wrote (325)	10/4/2000 1:33:38 PM
From: BulbaMan	Respond to of 1833

Cadus owns 30% of Axiom. In a another biotech boom, where an Axiom IPO gives it a $150 million market cap (or less than half of Biacore's market cap), the stake would be worth $45 million. Add the cash and potential yeast royalties and it's not beyond reason that if it was packaged correctly in a hot biotech market, Cadus could fetch $130 million. Let's say Icahn offers $2 per share (almost a 100% premium to the current KDUS share price) and gets the company for about $30 million. So, if he could later sell KDUS for the $130 million, he winds up with a $100 million profit – even for Icahn, this is not exactly chicken feed.